SLN Silence Therapeutics Corp: Price-to-Projected Revenue Ratio
Silence Therapeutics minimizes technological risks through large-scale contracts with global corporations in the siRNA therapy sector. The change in the forward P/S reflects current valuation dynamics, where the parameter is 2672.40. Financial stability is ensured by regular royalties from pharma behemoths. Market capitalization growth is driven by the success of zerlasiran and the platform's potential in treating rare pathologies.
SLN (Silence Therapeutics plc): analytical breakdowns and indicator data
- current price and projected stock value:
- company stock capitalization data:
- book value of equity indicators:
- debt and solvency information:
Total Debt to Capital Silence Therapeutics|SLN - Long-Term Liabilities to Capital|Short-Term Debt to Equity Ratio silence-therapeutics.com|SLN - Company Aggregate Debts|Debt to Book Value Silence Therapeutics Corp|SLN - Amount of Long-Term Liabilities|Company Short-Term Debts Silence Therapeutics|Quick Ratio silence-therapeutics.com
- financial results and valuation multiples details:
SLN - Net Income|Expected Profit Silence Therapeutics|SLN - Business Payback Period|Future Price to Earnings silence-therapeutics.com|SLN - Growth-Adjusted Market Cap to Net Income|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Silence Therapeutics plc|SLN - Profit before payment of interest, taxes and amortization|Earnings per share for the last twelve months Silence Therapeutics|SLN - Earnings per share for the last 12 months|Quarterly EPS earnings growth silence-therapeutics.com|SLN - Earnings per share growth this year|Net earnings per share growth forecast for next year Silence Therapeutics
- total revenue and sales volume data:
Fundamental company analysis:Silence Therapeutics plc (SLN)
For Silence Therapeutics (SLN), which develops high-precision RNA technologies for treating hematological pathologies, the forward P/S ratio reflects the company's market value relative to expected revenue. Analyzing this chart, an investor compares current brand capitalization costs with projected earnings to determine whether the business valuation is fair or if the asset is subject to speculative overheating.
Competing companies
Forward P/S Multiple TEM (Tempus Labs)|Qiagen N.V. - Price-to-Projected Revenue Ratio|IONS - Price-to-Projected Revenue Ratio|Market Cap to Future Revenue Ratio repligen.com|RNA: Forward P/S Multiple|CRISPR Therapeutics Inc (CRSP) - Forward P/S Multiple|WGS (GeneDx Holdings) - Forward P/S Multiple|RARE: Forward Price to Sales|Forward Price-to-Revenue Multiple BEAM (Beam Therapeutics Corp)|SRPT: Future Price to Revenue|Forward P/S Multiple TWST (Twist Bioscience Inc)|Market Cap to Expected Sales Ratio 10x Genomics Corp (TXG)|intelliatx.com - Forward P/S Multiple|Market Cap to Expected Sales Ratio Stoke STOK|biolifesolutions.com (BLFS) - Price-to-Projected Revenue Ratio|WVE - Market Cap to Expected Sales Ratio|Forward Price-to-Revenue Multiple MAZE|Forward Price-to-Revenue Multiple Sionna Therapeutics, Inc. (SION)|Forward Price-to-Revenue Multiple PRME (Prime Medicine Bio)|Market Cap to Expected Sales Ratio Taysha|uniQure Pharma - Forward Price-to-Revenue Multiple|MeiraGTx Holdings plc - Price-to-Projected Revenue Ratio|regenxbio.com - Forward P/S Multiple|Solid Bio (SLDB) - Forward Price-to-Revenue Multiple|OCGN: Forward P/S Multiple|Forward Price-to-Revenue Multiple Pacific Biosciences of California|BNTC (Benitec Biopharma Inc.) - Forward P/S Multiple|Market Cap to Projected Revenue DSGN (Design Therapeutics)|Forward P/S Multiple RCKT|Price-to-Projected Revenue Ratio FDMT (4D Molecular Therapeutics Inc)|Forward P/S Multiple LXEO (Lexeo Therapeutics Inc.)|Forward Price to Sales KRRO|EDIT - Price-to-Projected Revenue Ratio|Projected Price to Revenue ProQR Therapeutics (PRQR)|CDXS (Codexis Bio) - Forward Price-to-Revenue Multiple|Sangamo Therapeutics Inc. (SGMO) - Forward P/S Multiple|Price-to-Projected Revenue Ratio Nautilus Bio|Market Cap to Future Revenue Ratio Metagenomi Therapeutics MGX|Price-to-Projected Revenue Ratio Precision BioSciences (DTIL)|GBIO - Market Cap to Future Revenue Ratio|Forward P/S Multiple BOLD (Boundless Bio, Inc)|XCUR - Forward Price-to-Revenue Multiple|IMNN - Price-to-Projected Revenue Ratio|Market Cap to Future Revenue Ratio Phio Pharmaceuticals Corp|MBIO: Forward P/S Multiple|TransCode (RNAZ) - Forward P/S Multiple|BNGO (Bionano) - Forward P/S Multiple|Market Cap to Future Revenue Ratio Applied DNA Sciences, Inc. APDN|Forward P/S Multiple BLUE|ImmunoPrecise Antibodies Ltd - Market Cap to Projected Revenue|Price-to-Projected Revenue Ratio Omega Therapeutics OMGA|OMIC: Market Cap to Projected Revenue|RGLS: Forward Price-to-Revenue Multiple|Forward Price to Sales SYRS (Syros Pharmaceuticals, Inc.)|Telesis Bio, Inc. (TBIO) - Price-to-Projected Revenue Ratio|Future Price to Revenue TCON (TRACON)|Price-to-Projected Revenue Ratio Unity Biotechnology, Inc.
